This topic contains a solution. Click here to go to the answer

Author Question: What is the weakness of measuring gender inequality by means of status indicators? a. It does not ... (Read 92 times)

809779

  • Hero Member
  • *****
  • Posts: 579
What is the weakness of measuring gender inequality by means of status indicators?
 
  a. It does not take into account class differences that may occur within stratified societies.
  b. It does not allow the researcher to measure things that are not included as a norm.
  c. Because it involves numbers, there is a very high margin of error.
  d. People do not participate as freely in the collection of survey information as they do for interviews.

Question 2

Having male offspring within a patriarchal society or working to influence men on womens behalf is referred to as:
 
  a. influential power.
  b. informal power.
  c. nonstratified power.
  d. formal power.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

yuyiding

  • Sr. Member
  • ****
  • Posts: 357
Answer to Question 1

ANSWER:
a

Answer to Question 2

ANSWER:
b





 

Did you know?

The strongest synthetic topical retinoid drug available, tazarotene, is used to treat sun-damaged skin, acne, and psoriasis.

Did you know?

For about 100 years, scientists thought that peptic ulcers were caused by stress, spicy food, and alcohol. Later, researchers added stomach acid to the list of causes and began treating ulcers with antacids. Now it is known that peptic ulcers are predominantly caused by Helicobacter pylori, a spiral-shaped bacterium that normally exist in the stomach.

Did you know?

Approximately 500,000 babies are born each year in the United States to teenage mothers.

Did you know?

HIV testing reach is still limited. An estimated 40% of people with HIV (more than 14 million) remain undiagnosed and do not know their infection status.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library